Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sanofi gets rights to Exelixis' XL147 and XL765

Executive Summary

Three weeks after teaming up with Boehringer Ingelheim for immunology therapeutics, potentially gaining up to $354mm in that deal, Exelixis is now licensing two of its cancer candidates--XL147 and XL675--to Sanofi-Aventis in a collaboration that could bring the biotech over $1bn.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies